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Introduction: In rheumatoid arthritis (RA) patients receiving immunosuppressive treatments, vaccination against
Streptococcus pneumoniae is recommended. The objective of the study was to evaluate the effects of tacrolimus
(TAC) on immune response following administration of a 23-valent pneumococcal polysaccharide vaccine (PPSV23)
in patients with established RA.
Methods: Patients with RA (n = 133) were vaccinated with PPSV23. Patients were classified into TAC (n = 29),
methotrexate (MTX) (n = 55), control (n = 35), and TAC/MTX (n = 14) treatment groups. We measured the concentrations
of pneumococcal serotypes 6B and 23F by using an enzyme-linked immunosorbent assay and determined
antibody functionality by using a multiplexed opsonophagocytic killing assay, reported as the opsonization
index (OI), before and 4 to 6 weeks after vaccination. A positive antibody response was defined as at least a
twofold increase in the IgG concentration or as at least a 10-fold increase in the OI.
Results: IgG concentrations and OIs were significantly increased in all treatment groups after PPSV23 vaccination. The
TAC treatment group appears to respond in a manner similar to that of the RA control group in terms of 6B and 23F
serotype concentration and function. In contrast, the MTX group had the lowest immune response. Patients who
received a combination of TAC and MTX (TAC/MTX) also had a diminished immune response compared with
those who received TAC alone.
Conclusions: TAC monotherapy does not appear to impair PPSV23 immunogenicity in patients with RA, whereas
antibody production and function may be reduced when TAC is used with MTX. Thus, PPSV23 administration
during ongoing TAC treatment should be encouraged for infection-prone TAC-treated patients with rheumatic
diseases.
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Patients with rheumatoid arthritis (RA) have an increased
risk of developing an infectious disease as the underlying
conditions and immunomodulatory therapies weaken their
immune response [1]. The use of immunosuppressive
agents to treat RA may also contribute to this increased
risk. Therefore, routine immunizations are important to re-
duce infection-mediated morbidity and mortality [2, 3].
Given these concerns, the European League Against
Rheumatism treatment guidelines have recommended the
routine use of pneumococcal vaccines for immune-
compromised patients, including those who are receiving
tumor necrosis factor (TNF) inhibitors [4, 5]. Notably, the
response to vaccination varies among RA patients who are
receiving TNF inhibitor therapy with or without concomi-
tant corticosteroids or methotrexate (MTX) or both [6]. A
recent meta-analysis demonstrated that patients receiving
TNF inhibitors with MTX had a lower response to the
pneumococcal vaccine than those receiving TNF inhibitors
alone [7]. Furthermore, variable vaccine responses have
been reported for patients receiving other biological agents
that inhibit T-cell co-stimulation or deplete B cells with or
without concomitant corticosteroid or disease-modifying
antirheumatic drug (DMARD) treatment or both [8].
We previously reported that, in contrast to other bio-
logical treatment agents, tocilizumab, a humanized mono-
clonal antibody approved for RA treatment, does not
impair the immunogenicity of the 23-valent pneumococcal
polysaccharide vaccine (PPSV23) in patients with RA [9].
Therefore, we suspect that variation in the immune re-
sponse to a particular vaccine may depend on both the
type of vaccine and which biological agent the patient had
received. As intensive research in the field has led to the
development of a number of new treatment options for
patients with RA, it is essential to investigate the changes
in immunogenicity following treatment in order to deter-
mine the optimal vaccination options to effectively ward
off infection. For example, treatment modalities using cal-
cineurin inhibitors have become available for treatment of
RA diseases in the last decade [10]. This includes the
T cell-specific immunosuppressant, tacrolimus (TAC).
However, studies investigating the production of anti-
bodies following pneumococcal vaccination in patients
with RA diseases treated with TAC are limited [11, 12].
Thus, in this study, we have investigated the immunogen-
icity and tolerability of PPSV23 in Japanese patients with
RA following treatment with TAC.
Methods
Study design and patient population
We performed a randomized, double-blind, controlled
trial. Patients with clinically diagnosed RA were re-
cruited in Japanese National Hospital Organization hos-
pitals across Japan (n = 32) from September 2010 toDecember 2012. Eligible patients were also found to be
at risk for developing respiratory infections. Patients
with RA were divided into the following groups: (1) pa-
tients with rheumatoid lung disease, (2) patients with
RA treated with biological agents, and (3) patients who
received immunosuppressive agents. Patients were ex-
cluded if they had previously received a pneumococcal
vaccination. The following parameters were analyzed
when the patient was first admitted to the study: swollen
joint count, tender joint count, patient global assessment
of disease activity, physician global assessment of disease
activity, Health Assessment Questionnaire disability
index (HAQ-DI) score, serum levels of C-reactive pro-
tein (CRP), and Disease Activity Score 28-joint assess-
ment with CRP (DAS28 [CRP]) [13]. This study
complies with the principles of the Declaration of
Helsinki and was approved by the appropriate institu-
tional review boards at each participating center. All
patients provided written informed consent. This study
was approved by the ethics committees of the National
Hospital Organization central institutional review board
(0512014, 2012) and was registered with University Hos-
pital Medical Information Network Clinical Trials Registry
(UMIN000009566).Intervention
Patients were randomly assigned to receive either
0.5 ml (25 μg) of PPSV23 (Pneumovax NP; Merck
Sharp & Dohme Corp., Tokyo, Japan) or 0.5 ml of a
placebo (sodium chloride) subcutaneously in the upper
arm. The vaccines were prepared in a masked fashion
for those who administered it, blinding both the admin-
istrator of the vaccine and the patient to the type of
vaccine given. Vaccine and placebo were presented in
identical single-dose syringes and needle combinations
that were labelled with sequential study numbers only.
A statistician who was not on the study team carried
out the randomization by using a random number table
and numbered the containers accordingly.
Patients were instructed to record local reactions
(e.g., redness, swelling, and tenderness) and systemic
reactions (e.g., fever, nausea, and vomiting). Patients
were also monitored for 12 months after enrollment to
follow the development of pneumonia, including that
stemming from pneumococcal disease. Serum samples
were obtained immediately before and 4 to 6 weeks after
vaccination and stored at −30 °C until tested. An inde-
pendent investigator measured the serotype-specific IgG
geometric mean concentrations (GMCs) and opsonization
indices (OIs) by using the sera samples from patients
receiving PPSV23. The measurements were performed in
random order, and all clinical data were blinded to prevent
biases.
Migita et al. Arthritis Research & Therapy  (2015) 17:149 Page 3 of 9Enzyme-linked immunosorbent assays for serotype-specific
IgG
Enzyme-linked immunosorbent assays (ELISAs) for
serotype-specific IgG were performed to measure the
concentration of each type of antibody as previously de-
scribed [9]. Furthermore, to measure IgG specificity for
the 6B and 23F serotypes, we specifically performed our
ELISAs according to the World Health Organization
(WHO) standard procedure that used the international
reference serum, 89SF-3 (graciously supplied by Carl E.
Frasch). To improve the specificity of the assay, we per-
formed a pneumococcal cell wall polysaccharide (C-PS)
and pneumococcal 22F polysaccharide pre-absorption
step on the samples. The reference serum was pre-
absorbed with only C-PS [14, 15]. Detailed protocols are
available at [16].
Multiplexed opsonophagocytic assays
To measure antibody functionality against pneumococ-
cus, we performed multiplexed opsonophagocytic assays
for pneumococcal serotypes 6B and 23F by using differ-
entiated HL-60 cells and antibiotic-resistant target bac-
teria strains at the Research Institute for Microbial
Disease, Osaka University, as previously described [17].
The quality control serum included in each assay was
prepared from pooled sera of adults immunized with
PPV23. The OI was defined as the serum dilution that
led to 50 % death of target bacteria. Opsotiter 3, an
Excel-based data-processing program, was used to con-
vert colony counts to OIs in accordance with the WHO
protocol available at [18].
Antibody response
Fold increases relative to pre-vaccination values (ratios of
post-vaccination value to pre-vaccination value) were deter-
mined. Positive antibody response was defined as at least a
twofold increase in IgG concentrations or as at least a
10-fold increase in OIs as described previously [9].
Statistical analysis
Clinical and demographic data are expressed as mean ±
standard deviation or as a percentage. Comparisons were
made between the RA treatment groups before and after
administration of the vaccine by using an analysis of vari-
ance with post-hoc Tukey’s honesty significant difference
test. Differences in IgG concentrations or OI before and
after vaccination were compared by using the paired-
sample t test. Multivariate logistic regression analysis with
adjustment for baseline characteristics was used to assess
the relationship between positive antibody response to both
pneumococcal serotype and a set of predictor variables, in-
cluding age, gender, RA duration, current MTX, prednisol-
one use, TAC use, and serum IgG levels. A backward
stepwise selection procedure was used to select significantindependent variables. For all tests, probability values
(P values) of less than 0.05 were considered statistically sig-
nificant. All calculations were performed by using Excel
Statistical Analysis 2008 (SSRI Co., Ltd., Tokyo, Japan) or
PASW Statistics version 20 (SPSS Japan Inc., Tokyo, Japan).
Results
Clinical and demographic characteristics
In total, 989 subjects were assessed for eligibility, and 929
patients were recruited and randomly assigned (Additional
file 1: Figure S1). Paired serum samples were obtained be-
fore and after vaccination from 703 subjects, 353 of which
received PPV23. Patients receiving PPSV23 were divided
into the following three groups according to their ongoing
anti-RA therapy: TAC monotherapy (2.0 ± 0.7 mg/day,
TAC group, n = 29), MTX monotherapy (7.8 ± 2.4 mg/
week, MTX group, n = 55), and DMARD (salazosulfapyri-
dine 14/35, bucillamine 5/35, penicillamine 1/35, sodium
aurothiomalate 1/35, ignatimod 1/35) or steroid (13/35)
treatments (RA control group; n = 35). Patients’ clinical and
demographic characteristics are shown in Table 1. All par-
ticipants fulfilled the criteria of safety required for vaccine
injection, and no serious side effects were observed after
vaccination.
Serotype-specific IgG concentrations
Four to six weeks after pneumococcal vaccination, the
GMCs of both serotype 6B- and 23F-specific IgG were in-
creased in all three groups (P < 0.00001, Table 2). However,
these elevated GMC responses were not observed in the
placebo group (Additional file 2: Table S1). Furthermore,
the post-vaccination GMC of serotype 6B-specific anti-
bodies was not significantly different when the three
treatment groups were compared, implying that a simi-
lar increase was observed regardless of TAC or MTX
treatment. However, the concentration of serotype 23F-
specific antibodies post-vaccination was significantly
higher in patients who received TAC compared with
the MTX treatment group (P = 0.005).
Opsonophagocytic killing assays
The post-vaccination OIs increased significantly in all treat-
ment groups. The ratios between pre- and post-vaccination
are provided in Table 2. Whereas there was no significant
difference observed between the TAC and control groups,
there were significant differences in the post-vaccination
OIs specific to 6B and 23F between the MTX and TAC
treatment groups, and the TAC treatment group had higher
OIs than the MTX group.
Antibody response rates
The antibody response rates, given as the percentage of pa-
tients with a positive antibody response, for patients in the
Table 2 Concentrations of pneumococcal polysaccharide antigen serotype-specific IgG antibodies and opsonization indices in the
rheumatoid arthritis treatment groups before and after 23-valent pneumococcal polysaccharide vaccination
MTX group n = 55 TAC group n = 29 P values between
treatment groups
IgG GMCs, μg/ml
6B Before 0.84 (0.58 to 1.11) 1.42 (0.86 to 1.97) 1.61 (1.11 to 2.11) NS
After 4.05 (2.13 to 5.97)* 4.36 (2.17 to 6.55)* 8.35 (2.79 to 13.91)* NS
Fold increase 2.38 (1.41 to 5.62) 1.75 (1.15 to 3.11) 2.04 (1.71 to 5.76) NS
23F Before 1.17 (0.85 to 1.48) 1.79 (1.33 to 2.25) 1.38 (0.68 to 2.08) NS
After 11.61 (4.16 to 19.07)* 7.41 (4.48 to 10.33)* 16.73 (7.81 to 25.65)* NS
Fold increase 3.36 (1.85 to 9.42) 2.00 (1.27 to 5.48) 7.63 (3.70 to 18.85) 0.005 (MTX vs. TAC)
GM-OIs
6B Before 17.24 (10.96 to 23.53) 150.79 (14.85 to 286.74) 262.89 (56.54 to 469.25) NS
After 981.15 (407.24 to 1555.05)* 584.29 (270.29 to 898.28)* 2026.54 (1047.56 to 3005.51)* 0.002 (MTX vs. TAC)
Fold increase 10.22 (1.92 to 79.48) 2.57 (1.22 to 22.40) 20.80 (3.86 to 70.38) NS
23F Before 63.21 (−6.79 to 133.20) 52.11 (14.04 to 90.18) 164.57 (−129.84 to 458.98) NS
After 713.49 (307.97 to 1119.01)* 724.56 (336.93 to 1112.19)* 1583.04 (773.21 to 2392.86)* 0.013 (MTX vs. TAC)
Fold increase 6.86 (2.50 to 27.14) 3.75 (1.47 to 38.32) 64.38 (11.59 to 231.22) 0.048 (MTX vs. TAC)
IgG GMCs and GM-OIs are expressed as the mean (95 % confidence interval). Fold increases are expressed as the median (interquartile range). Differences between pre- and
post-vaccination GMCs of serotype-specific IgG were assessed by using a paired-sample t test. The three treatment groups were compared by using Kruskal-Wallis test with a
Scheffé post-hoc test
MTX methotrexate, TAC tacrolimus, GMC geometric mean concentration, GM-OI geometric mean opsonization index, NS not significant
*P < 0.00001 compared with pre-vaccination IgG GMCs or GM-OIs
Table 1 Clinical and demographic characteristics of rheumatoid arthritis patients prior to pneumococcal vaccination
RA control MTX group TAC group TAC +MTX group
n = 35 n = 55 n = 29 n = 14
Male/female 12/23 11/44 9/20 1/13
Age in years, mean ± SD 70.54 ± 10.84 63.80 ± 11.50 69.28 ± 9.87 61.00 ± 11.68
Weight in kg, mean ± SD 53.32 ± 9.54 52.87 ± 11.83 52.22 ± 12.24 50.84 ± 9.42
BMI, mean ± SD 21.79 ± 3.47 21.69 ± 3.69 21.84 ± 4.43 21.51 ± 3.23
RA duration in years, mean ± SD 11.66 ± 12.52 14.11 ± 10.90 10.52 ± 9.74 12.14 ± 7.07
MTX dose in mg/week, mean ± SD - 7.80 ± 2.37 - 8.29 ± 3.22
TAC dose in mg/day, mean ± SD - - 2.05 ± 0.74 1.64 ± 0.57
Use of prednisolone, number (%) of patients 21 (60.0) 30 (54.5) 21 (72.4) 6 (42.9)
Prednisolone dose in mg/day, mean ± SD 6.06 ± 4.23 4.98 ± 2.97 3.89 ± 1.99 3.00 ± 1.26
DAS28 (CRP), mean ± SD 2.79 ± 1.17 2.61 ± 0.98 2.79 ± 1.23 2.10 ± 0.71
HAQ-DI, mean ± SD 0.85 ± 0.84 0.62 ± 0.76 0.76 ± 0.88 0.53 ± 0.41
SDAI, mean ± SD 9.03 ± 6.32 8.15 ± 7.33 10.36 ± 10.63 4.60 ± 4.06
CDAI, mean ± SD 7.83 ± 5.40 7.45 ± 6.73 9.68 ± 10.51 3.95 ± 3.84
IP (%) 6 (17.1) 7 (12.7) 13 (44.8) 0
COPD (%) 3 (8.6) 1 (1.8) 2 (6.9) 0
Smoking history (%) 3 (8.6) 5 (9.1) 3 (10.3) 1 (7.1)
Data were obtained immediately before pneumococcal vaccination
RA rheumatoid arthritis, MTX methotrexate, TAC tacrolimus, SD standard deviation, BMI body mass index, DAS28 disease activity score 28, CRP C-reactive protein,
HAQ-DI Health Assessment Questionnaire disability index score, SDAI simplified disease activity index, CDAI clinical disease activity index, IP interstitial pneumonia,
COPD chronic obstructive pulmonary disease
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treated RA control group for both serotype 6B and 23F
(Fig. 1a). However, the serotype 6B- and 23F-specific anti-
body response rates were significantly higher in the TAC
group (6B 86.2 %, 23F 93.1 %) compared with the MTX
group (6B 56.4 %, 23F 65.5 %; P = 0.006 and P = 0.005, re-
spectively). Furthermore, the percentage of patients with a
positive antibody response for both strains was significantly
greater in the TAC treatment group (79.3 %) compared
with the MTX group (50.9 %, P = 0.011). For OIs specific to
serotype 6B and 23F (Fig. 1b), the TAC group (6B 57.7 %,
23F 82.1 %) showed a higher antibody response rate than
did the MTX group (6B 34.6 %, P = 0.052; 23F 44.2 %,
P = 0.001). For both strains, a higher proportion of the
TAC-treated patients responded to pneumococcal vac-
cination compared with the patients who received
MTX; however, this difference was not significant
(46.2 % compared with 25.0 %, respectively; P = 0.059).Fig. 1 Flow diagram of patient recruitment. Comparison of post-vaccination pa
of patients with an increase in 6B and 23F serotype-specific IgG concentration g
with MTX. b Percentage of patients with an increase in OI for serotypes 6B and
(TAC versus MTX). Data were compared by using the chi-squared test or Fisher’
rheumatoid arthritis, TAC tacrolimusComparison between TAC monotreatment and TAC/MTX
combination treatment
Notably, TAC is used primarily as a monotherapy, and the
combined use of TAC and MTX is limited in Japan, as
highlighted in a recent patient survey from this country
[19]. Therefore, we were not surprised that only 14 RA pa-
tients receiving both TAC and MTX were enrolled in this
study (Table 1). When these patients are compared with
those receiving TAC monotherapy, it appears that both
groups had a significant increase in the GMC and OI of
the 6B and 23F serotypes after PPSV23 vaccination
(Table 3). However, the post-vaccination GMC and the
OIs for both serotypes were significantly lower in the pa-
tients receiving TAC/MTX combination therapy com-
pared with those receiving TAC monotherapy. Similarly, a
lower proportion of RA patients receiving TAC/MTX
combination therapy had a geometric mean titer increase
greater than twofold for both serotypes or an increase inrameters in patients receiving TAC or MTX monotreatment. a Percentage
reater than twofold. *P= 0.006, **P= 0.005, ***P= 0.011 for TAC compared
23F greater than 10-fold. *P= 0.001 (TAC versus RA control) and P= 0.001
s exact probability test. MTX methotrexate, OI opsonization index, RA
Table 3 Concentrations of pneumococcal polysaccharide antigen serotype-specific IgG antibodies and opsonization indices in the
rheumatoid arthritis treatment groups before and after 23-valent pneumococcal polysaccharide vaccination
TAC +MTX group n = 14 TAC group n = 29 P value
IgG GMCs, μg/ml
6B Before 2.48 (0.92 to 4.04) 1.61 (1.11 to 2.11) 0.288
After 11.89 (−2.25 to 26.03)* 8.35 (2.79 to 13.91)*** 0.551
Fold increase 1.39 (1.10 to 2.67) 2.04 (1.70 to 5.40) 0.023
23F Before 2.02 (0.93 to 3.11) 1.38 (0.68 to 2.08) 0.114
After 4.94 (2.10 to 7.77)* 16.73 (7.81 to 25.65)*** 0.017
Fold increase 1.85 (1.14 to 3.82) 7.63 (3.70 to 18.85) P < 0.0001
GM-OIs
6B Before 167.43 (34.41 to 300.45) 262.89 (56.54 to 469.25) 0.471
After 715.85 (−138.24 to 1569.94)** 2026.54 (1047.56 to 3005.51)*** 0.043
Fold increase 5.50 (2.31 to 10.60) 20.80 (3.86 to 70.38) 0.053
23F Before 9.50 (2.60 to 16.40) 164.57 (−129.84 to 458.98) 0.227
After 91.14 (−13.42 to 195.70)* 1583.04 (773.21 to 2392.86)*** P < 0.0001
Fold increase 3.51 (1.00 to 8.00) 64.38 (11.59 to 231.22) P < 0.0001
IgG GMCs and GM-OIs are expressed as the mean (95 % confidence interval). Fold increases are expressed as the median (interquartile range). Differences between pre- and
post-vaccination GMCs of serotype-specific IgG were assessed by using a paired-sample t test. P values were calculated with chi-squared test for qualitative data
TAC tacrolimus, MTX methotrexate, GMC geometric mean concentration, GM-OI geometric mean opsonization index
*P < 0.005, **P < 0.001, ***P < 0.00001, compared with pre-vaccination IgG GMCs or GM-OIs
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data indicate that the combination of TAC and MTX
treatment may cause reduced immune responsiveness
against the pneumococcal vaccine PPSV23.Predictive factors for antibody response to PPSV23
In a multivariate logistic regression analysis, TAC use was
not identified as the predictive factor for antibody re-
sponse to pneumococcal vaccination for either IgG con-
centrations or OIs (Additional file 3: Table S2, Additional
file 4: Table S3). The negative association of current MTX
use with antibody response was confirmed for both IgG
concentrations specific to serotypes 6B and 23F (odds ra-
tio 0.297, 95 % confidence interval 0.129 to 0.684,
P = 0.004, Additional file 3: Table S2).Discussion
Pneumococcal vaccination has been advocated for im-
munocompromised patients receiving the immunosup-
pressive RA treatments, such as TAC [20]. TAC is a
type of calcineurin inhibitor that blocks T-cell cytokine
production and indirectly affects B-cell activation [21].
Thus, a slight decrease in antibody production could be
expected from this type of treatment. Notably, TAC has
been used previously to prevent organ rejection follow-
ing transplant and graft-versus-host disease after bone
marrow transplants as well as for the treatment of myasthe-
nia gravis, lupus nephritis, and ulcerative colitis [22]. How-
ever, the effects of TAC on the immunogenicity ofpneumococcal vaccination are inconsistent in transplant re-
cipients receiving treatment [23–25]. For example, Broeders
et al. [26] previously assessed the immunogenicity of a poly-
saccharide vaccine in renal transplant recipients receiving
TAC treatment and demonstrated that, although the pro-
tective effects of the vaccine were variable, all patients col-
lectively produced suboptimal responses [26]. We suspect
that these inconsistencies may be accounted for by the in-
trinsic effect of B-cell function under these treatment
conditions.
In April 2005, TAC was approved as a treatment op-
tion for Japanese RA patients who had responded in-
appropriately to conventional treatments; this approval
was subsequently granted in Canada, Korea, and Hong
Kong [27]. However, our understanding concerning the
interaction and effects of this treatment on vaccine
function is limited. Therefore, to evaluate the immune
response to PPSV23 in RA patients receiving TAC, we
monitored several immune response parameters, in-
cluding patient health, antibody concentration, and OI,
following PPSV23 administration to patients receiving
TAC and MTX. To this end, we examined the GMC of
serotype 6B and 23F antibodies pre-vaccination and 4 to
6 weeks post-vaccination and found that both serotypes
increased significantly in untreated and treated (TAC
and MTX monotherapy) patients. It also appears that,
for certain serotypes, this PPSV23 vaccine evoked a
greater immunogenic response (i.e., a higher concentra-
tion and functional response) in RA patients receiving
TAC compared with those receiving MTX. These
Fig. 2 Comparison of post-vaccination parameters in patients receiving TAC monotreatment or TAC/MTX combination treatment. a Percentage
of patients with an increase in 6B and 23F serotype-specific IgG concentration greater than twofold. *P= 0.005, **P= 0.028, ***P= 0.001, for TAC compared
with TAC/MTX. b Percentage of patients with an increase in OI for serotypes 6B and 23F greater than 10-fold. *P< 0.0001 for TAC compared with TAC/
MTX. Data were compared by using the chi-squared test or Fisher’s exact probability test. MTX methotrexate, OI opsonization index, TAC tacrolimus
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cell-independent polysaccharide antigens in RA patients
following TAC-based immunosuppressive therapy is pre-
served in comparison with conventional MTX therapy.
Combination therapy using both TAC and MTX had a de-
creased immune response to the PPSV23 vaccine in com-
parison with TAC alone. Taken together, these data
indicate that a greater proportion of TAC-treated pa-
tients responded to PPSV23 more efficiently compared
with patients who received MTX alone or in conjunc-
tion with TAC.
Notably, the pneumococcal vaccine used in this study
consists almost exclusively of capsular polysaccharides
[28]. This is important to note, as antibody production
by B cells often requires “help” from T cells; however,highly repetitive polysaccharide structures have been
shown to induce T cell-independent antibody production
in B cells [29]. Thus, we suspect that the therapeutic im-
munosuppression observed in the TAC-treated RA pa-
tients in this study affects mainly T-cell function as this
would not significantly alter the T cell-independent im-
mune response to this specific pneumococcal vaccin-
ation. Furthermore, this conclusion is corroborated by
other studies in this field [30]; however, additional work
should be conducted by using vaccines with less repeti-
tive polysaccharide structures. Immunogenicity of tet-
anus toxoid and 23-valent pneumococcal vaccinations
was impaired in healthy subjects receiving abatacept, a
selective T-cell co-stimulation modulator [31]. Also,
treatment with abatacept was associated with diminished
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(PCV 7) [8]. Our data were not consistent with this pre-
vious study by Tay et al., who used the same PPSV23
vaccination [31]. The differences in the subjects (healthy
subjects versus RA patients) or T cell-targeted treat-
ments (abatacept versus tacrolimus) may contribute to
the discrepancies between our data and those of a previ-
ous study [31]. Protein-conjugated vaccines, which in-
duce T cell-dependent immune response, may induce
superior immune responses compared with the polysac-
charide vaccine. However, further investigations for the
immunogenicity of these T cell-dependent vaccines under
T cell-targeted immunosuppressive treatments will be
needed.
The primary limitation of this study is the relatively
small number of patients with RA in each group, par-
ticularly for TAC/MTX combination treatment (n = 14).
Sample size calculations were based on our previous
study obtained RA patients receiving PPSV23 vaccin-
ation [9]. In this study, RA patients receiving MTX
achieved the fold induction of 6B-specific (mean ± SD;
1.6 ± 0.8) and 23F-specific (mean ± SD; 2.1 ± 1.0) IgG
after 4 to 6 weeks from vaccination. Under this assump-
tion, 33 (for 6B) or 27 (for 23F) evaluable patients sam-
ples for each group were needed with a one-tailed t test
with significance of 0.05 and 80 % power to detect 40 %
reduction of GMC fold induction between the MTX
group and the TAC/MTX group. Furthermore, we
choose to investigate serotypes 6B and 23F because they
are the main causative serotypes of penicillin-resistant
pneumococcal pneumonia in Japan [32]. Although this
allowed us to focus solely on these important serotypes,
the effects of TAC on other serotypes during the
PPSV23 vaccine-induce immune response are still un-
known. Lastly, the antibody concentrations necessary for
protection against invasive pneumococcal disease in
adults have not been clearly defined [33]. Although we
used the thresholds provided by previous studies, namely
a twofold increase in IgG concentration and a 10-fold
increase in the OI, to measure the positive antibody re-
sponse to PPSV23 in this study, the suitability of these
thresholds to predict prevention of pneumococcal infec-
tion has not been widely investigated.Conclusions
We have shown that pneumococcal vaccination for RA
patients receiving TAC treatment induced an adequate
immunogenic response to the PPSV23 vaccine. However,
diminished responsiveness to PPSV23 was observed in
patients receiving TAC and concomitant MTX. On the
basis of these data, we believe that pneumococcal vac-
cination and TAC treatment should be used more fre-
quently in infection-prone patients with RA.Additional files
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